Pink Sheet Podcast: BIOSECURE Act Advances, Trial Diversity Sticks, & More
Podcast
Regulatory & Compliance
Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, and Interim Editor in Chief Nielsen Hobbs discuss the implications of the BIOSECURE Act on the pharma industry in the US and China, as well as other hot topics.
It seems like there’s a lot of level setting the FDA and Congress are going to have to do here.
Related products
Pink Sheet
The leader in pharmaceutical news and regulatory trend analysis
Global Patient Insights
Enabling sponsors to optimize investigator selection and hit diversity goals faster
Citeline Connect Marketplace
A robust recruitment network of 100+ recruitment organizations powering more efficient, effective trial enrollment
OCT 30, 2024
Article
Regulatory & Compliance
Artificial Intelligence Regulation
Drug sponsors strive to make the best use of artificial intelligence, but doing so requires understanding where health authorities are drawing the lines. Download a sample of our coverage from the US, Europe, and Asia of the emerging framework for AI regulation.
OCT 30, 2024
Article
Regulatory & Compliance
EU’s Pharma Legislative Reform
Every drug sponsor wants to make the best use of Artificial Intelligence, but doing so requires understanding where health authorities are drawing the lines. Download a sample of our coverage from Asia, Europe and the United States of the emerging framework for AI regulation.
